ArticleCancer medicine2013
Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients.
Article in Cancer medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- FOXM1 regulates platelet-induced anoikis resistance in pancreatic cancer cells.Cell communication and signaling : CCS · 2026Article
- Comprehensive analysis of Epha10 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in non-small cell lung cancer.Scientific reports · 2024Article
- A Novel Gene Signature Associated With "E2F Target" Pathway for Predicting the Prognosis of Prostate Cancer.Frontiers in molecular biosciences · 2022Article
- The intracellular domains of the EphB6 and EphA10 receptor tyrosine pseudokinases function as dynamic signalling hubs.The Biochemical journal · 2021Article
- Coexpression of EphA10 and Gli3 promotes breast cancer cell proliferation, invasion and migration.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2021Article
- Review
- The Role of the Eph Receptor Family in Tumorigenesis.Cancers · 2021Review
- The catalytically defective receptor protein tyrosine kinase EphA10 promotes tumorigenesis in pancreatic cancer cells.Cancer science · 2020Article
- Whole Exome and Transcriptome RNA-Sequencing Model for the Diagnosis of Prostate Cancer.ACS omega · 2020Article
- Overexpressed gene signature of EPH receptor A/B family in cancer patients-comprehensive analyses from the public high-throughput database.International journal of clinical and experimental pathology · 2020Article
- Review
- Prospects for pharmacological targeting of pseudokinases.Nature reviews. Drug discovery · 2019Review
- EphA10 and EphB3 are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas.International journal of clinical and experimental pathology · 2018Article
- Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers.BioMed research international · 2018Review
- The role of Eph/ephrin molecules in stromal–hematopoietic interactions.International journal of hematology · 2016Review
- Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA.International journal of nanomedicine · 2016Article
- Development of novel drug delivery systems using phage display technology for clinical application of protein drugs.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2016Review
- Decreased expression of receptor tyrosine kinase of EphB1 protein in renal cell carcinomas.International journal of clinical and experimental pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eph receptor A10 (EphA10) is a valuable breast cancer marker that is highly expressed in breast cancer tissues by comparison with normal breast tissues, as we previously reported. However, the role of EphA10 expression in breast cancer is not well understood. Here, we have analyzed the expression of EphA10 at the mRNA- and protein-level in clinical breast cancer tissues and then evaluated the relationship with clinicopathological parameters for each sample. EphA10 mRNA expression was quantified by real-time polymerase chain reaction using complimentary DNA (cDNA) samples derived from breast cancer patients. Lymph node (LN) metastasis and stage progression were significantly correlated with EphA10 expression at the mRNA level (P = 0.0091 and P = 0.034, respectively). Furthermore, immunohistochemistry (IHC) staining of breast cancer tissue microarrays (TMAs) revealed that EphA10 expression at the protein level was also associated with LN metastasis and stage progression (P = 0.016 and P = 0.011, respectively). These results indicate that EphA10 expression might play a role in tumor progression and metastasis. Our findings will help elucidate the role of EphA10 in clinical breast cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.